Insulin and insulin-like growth factor-I (IGF-I) receptor overexpression in breast cancers leads to insulin/IGF-I hybrid receptor overexpression: evidence for a second mechanism of IGF-I signaling.

The insulin receptor (IR) form hybrids with the closely related insulin-like growth factor-I (IGF-I) receptor (IGF-I-R). Because most human breast carcinomas overexpress both the IR and the IGF-I-R, we evaluated whether the insulin/IGF-I hybrid receptor (Hybrid-R) is also overexpressed in these tumors and what role it plays in breast cancer biology. Using specific ELISAs and Western blots, we measured Hybrid-R content and function in 8 human cultured breast cancer cell lines and 39 human breast cancer specimens. Hybrid-R content and function were also compared to the content and function of the IR and the IGF-I-R. Hybrid-R content exceeded the IGF-I-R content in >75% of breast cancer specimens and was directly related to the molar ratio of both the IR and IGF-I-R content, suggesting that Hybrid-R formation occurred by random assembly of IR and IGF-I-R half-receptors. Hybrid-Rs became tyrosine autophosphorylated when breast cancer cells were exposed to IGF-I but not when they were exposed to insulin. In cells with an elevated Hybrid-R content, Hybrid-R autophosphorylation in response to IGF-I exceeded IGF-I-R autophosphorylation, suggesting that most of the IGF-I effect occurred via the Hybrid-R. Furthermore, Hybrid-Rs mediated growth in response to IGF-I, as indicated by experiments with blocking antibodies to the IGF-I-R. These data indicated therefore that: (a) Hybrid-Rs are present and play a major role in mediating the IGF-I signal in breast cancer; (b) their expression is directly related to IR overexpression; and (c) potential therapies designed to block IGF-I actions in breast cancer must take into account the role of these Hybrid-Rs.

[1]  M. Mathieu,et al.  Insulin receptor expression and clinical outcome in node-negative breast cancer. , 1997, Proceedings of the Association of American Physicians.

[2]  K. Siddle,et al.  Insulin receptor/IGF-I receptor hybrids are widely distributed in mammalian tissues: quantification of individual receptor species by selective immunoprecipitation and immunoblotting. , 1997, The Biochemical journal.

[3]  A. Costantino,et al.  Insulin Receptor What Role in Breast Cancer? , 1997, Trends in Endocrinology & Metabolism.

[4]  R. Dickson,et al.  Growth factors in breast cancer. , 1995, Endocrine reviews.

[5]  C. Roberts,et al.  Growth inhibition of MCF-7 breast cancer cells by stable expression of an insulin-like growth factor I receptor antisense ribonucleic acid. , 1995, Endocrinology.

[6]  J. Olefsky,et al.  A functional assessment of insulin/insulin-like growth factor-I hybrid receptors. , 1995, Endocrinology.

[7]  R. Baserga.  The insulin-like growth factor I receptor: a key to tumor growth? , 1995, Cancer research.

[8]  D. Coppola,et al.  Rat glioblastoma cells expressing an antisense RNA to the insulin-like growth factor-1 (IGF-1) receptor are nontumorigenic and induce regression of wild-type tumors. , 1994, Cancer research.

[9]  C. Yip,et al.  Deletion of residues 485-599 from the human insulin receptor abolishes antireceptor antibody binding and influences tyrosine kinase activation. , 1994, Molecular endocrinology.

[10]  Y. Fujita-Yamaguchi,et al.  Characterization of human placental insulin-like growth factor-I/insulin hybrid receptors by protein microsequencing and purification. , 1993, Biochemistry.

[11]  G M Clark,et al.  Insulin-like growth factor-I receptors are overexpressed and predict a low risk in human breast cancer. , 1993, Cancer research.

[12]  J. Pessin,et al.  Relationship between alpha subunit ligand occupancy and beta subunit autophosphorylation in insulin/insulin-like growth factor-1 hybrid receptors. , 1993, The Journal of biological chemistry.

[13]  K. Siddle,et al.  Purified hybrid insulin/insulin-like growth factor-I receptors bind insulin-like growth factor-I, but not insulin, with high affinity. , 1993, The Biochemical journal.

[14]  K. Siddle,et al.  A monoclonal anti-peptide antibody reacting with the insulin receptor beta-subunit. Characterization of the antibody and its epitope and use in immunoaffinity purification of intact receptors. , 1992, The Biochemical journal.

[15]  M. Stampfer,et al.  Insulin receptor expression and function in human breast cancer cell lines. , 1992, Cancer research.

[16]  A. Ullrich,et al.  A panel of monoclonal antibodies for the type I insulin-like growth factor receptor. Epitope mapping, effects on ligand binding, and biological activity. , 1992, The Journal of biological chemistry.

[17]  V. Macaulay,et al.  Insulin-like growth factors and cancer. , 1992, British Journal of Cancer.

[18]  A. Costantino,et al.  Overexpression of insulin receptors in fibroblast and ovary cells induces a ligand-mediated transformed phenotype. , 1991, Molecular endocrinology.

[19]  R. Brand,et al.  Elevated insulin receptor content in human breast cancer. , 1990, The Journal of clinical investigation.

[20]  W. Rutter,et al.  The cysteine-rich domains of the insulin and insulin-like growth factor I receptors are primary determinants of hormone binding specificity. Evidence from receptor chimeras. , 1990, The Journal of biological chemistry.

[21]  J. Russo,et al.  Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. , 1990, Cancer research.

[22]  A. Ullrich,et al.  Receptors for insulin and insulin-like growth factor-I can form hybrid dimers. Characterisation of hybrid receptors in transfected cells. , 1990, The Biochemical journal.

[23]  W. Rutter,et al.  Overexpression of the human insulinlike growth factor I receptor promotes ligand-dependent neoplastic transformation , 1990, Molecular and cellular biology.

[24]  C. Osborne,et al.  Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice. , 1989, The Journal of clinical investigation.

[25]  V. Duronio,et al.  Insulin-like growth factor I receptor beta-subunit heterogeneity. Evidence for hybrid tetramers composed of insulin-like growth factor I and insulin receptor heterodimers. , 1989, The Journal of biological chemistry.

[26]  I. Goldfine,et al.  Effect of monoclonal antibodies on human insulin receptor autophosphorylation, negative cooperativity, and down-regulation. , 1987, The Journal of biological chemistry.

[27]  K. Siddle,et al.  Monoclonal antibodies reacting with multiple epitopes on the human insulin receptor. , 1986, The Biochemical journal.

[28]  Martha R. Stampfer,et al.  Isolation and growth of human mammary epithelial cells , 1985 .

[29]  M. Stampfer,et al.  Induction of transformation and continuous cell lines from normal human mammary epithelial cells after exposure to benzo[a]pyrene. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[30]  M. Preece,et al.  Purification of insulin-like growth factor I , 1984, Regulatory Peptides.

[31]  P. Cuatrecasas,et al.  Monoclonal antibodies to receptors for insulin and somatomedin-C. , 1983, The Journal of biological chemistry.

[32]  R. Roth,et al.  Monoclonal antibodies to the human insulin receptor block insulin binding and inhibit insulin action. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[33]  W. Sly,et al.  Insulin-like growth factor receptor expression and function in human breast cancer. , 1990, Cancer research.

[34]  H. Oberlander.  Tissue Culture Methods , 1980 .